Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

39.64 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript ↗

October 29, 2024

HRMY earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Analyst Expectations For Harmony Biosciences's Future ↗

October 29, 2024

Via Benzinga

Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat ↗

October 29, 2024

The company is focused on developing its pipeline of sleep and epilepsy drugs.

Via Investor's Business Daily

Earnings Outlook For Harmony Biosciences ↗

October 28, 2024

Via Benzinga

Breaking Down Harmony Biosciences: 6 Analysts Share Their Views ↗

October 02, 2024

Via Benzinga

Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says ↗

September 10, 2024

UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026.

Via Benzinga

Unveiling 6 Analyst Insights On Harmony Biosciences ↗

September 10, 2024

Via Benzinga

Analyst Expectations For Harmony Biosciences's Future ↗

August 06, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts ↗

June 21, 2024

Via Benzinga

Key Takeaways From Harmony Biosciences Analyst Ratings ↗

April 30, 2024

Via Benzinga

Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript ↗

August 06, 2024

HRMY earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

August 06, 2024

From Harmony Biosciences

Via GlobeNewswire

7 Cheap Biotech Stocks With Major Upside Potential ↗

July 09, 2024

While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.

Via InvestorPlace

7 Undervalued Biotech Stocks to Buy for Big-Time Returns ↗

July 01, 2024

The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.

Via InvestorPlace

Evaluating Harmony Biosciences: Insights From 8 Financial Analysts ↗

March 28, 2024

Via Benzinga

Analyst Ratings For Harmony Biosciences ↗

February 22, 2024

Via Benzinga

NASDAQ:HRMY stands out as a growth opportunity that won't break the bank. ↗

January 10, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:HRMY.

Via Chartmill

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In ↗

May 14, 2024

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.

Via Benzinga

Topics Cannabis

Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript ↗

April 30, 2024

HRMY earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024 ↗

April 30, 2024

HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View ↗

April 30, 2024

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with...

Via Benzinga

Topics Earnings

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

April 30, 2024

From Harmony Biosciences

Via GlobeNewswire

Updates: HRMY, MELI, SWAV ↗

February 28, 2024

Another day, another slew of quarterly update reports for our followed stocks.

Via Talk Markets

Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript ↗

February 22, 2024

HRMY earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

February 22, 2024

From Harmony Biosciences

Via GlobeNewswire

The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024 ↗

February 12, 2024

Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently.

Via InvestorPlace

The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024 ↗

February 07, 2024

Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks.

Via InvestorPlace

NASDAQ:HRMY: good value for what you're paying. ↗

January 25, 2024

In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.